Neovacs - strong bullish trend expected

Results of IFN Kinoide on Lupus research are very significant (95% efficacy observed). Volume increase strongly on the biotech and strong breakout of the 0.25 resistance has been observed. Pullback on the 0.25 level is resolved and the stock is now in perfect conditions for a bullish rally. First target is 0.5
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Get Help Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing Get Help Ideas Published Followers Following Private Messages Chat Sign Out